{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T21:52:59Z","timestamp":1787003579327,"version":"build-2736575974"},"reference-count":82,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,28]],"date-time":"2024-12-28T00:00:00Z","timestamp":1735344000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,12,28]],"date-time":"2024-12-28T00:00:00Z","timestamp":1735344000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-024-82266-1","type":"journal-article","created":{"date-parts":[[2024,12,27]],"date-time":"2024-12-27T22:38:40Z","timestamp":1735339120000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Identification of a novel immune checkpoint-related gene signature predicts prognosis and immunotherapy in breast cancer and experiment verification"],"prefix":"10.1038","volume":"14","author":[{"given":"Ke","family":"Yin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yangyang","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinqiu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shenchao","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunxu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongping","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,28]]},"reference":[{"key":"82266_CR1","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel, R. L., Giaquinto, A. N. & Jemal, A. Cancer statistics 2024. CA Cancer J. Clin. 74, 12\u201349. https:\/\/doi.org\/10.3322\/caac.21820 (2024).","journal-title":"CA Cancer J. Clin."},{"key":"82266_CR2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.33588(2021)","author":"J Ferlay","year":"2020","unstructured":"Ferlay, J. et al. Cancer statistics for the year 2020: An overview. Int. J. Cancer https:\/\/doi.org\/10.1002\/ijc.33588(2021) (2020).","journal-title":"Int. J. Cancer"},{"key":"82266_CR3","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung, H. et al. Global cancer statistics 2020: globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71, 209\u2013249. https:\/\/doi.org\/10.3322\/caac.21660 (2021).","journal-title":"CA Cancer J. Clin."},{"key":"82266_CR4","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray, F. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 68, 394\u2013424. https:\/\/doi.org\/10.3322\/caac.21492 (2018).","journal-title":"CA Cancer J. Clin."},{"key":"82266_CR5","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.7150\/ijbs.21635","volume":"13","author":"YS Sun","year":"2017","unstructured":"Sun, Y. S. et al. Risk factors and preventions of breast cancer. Int. J. Biol. Sci. 13, 1387\u20131397. https:\/\/doi.org\/10.7150\/ijbs.21635 (2017).","journal-title":"Int. J. Biol. Sci."},{"key":"82266_CR6","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1056\/NEJMoa1600249","volume":"375","author":"HG Welch","year":"2016","unstructured":"Welch, H. G., Prorok, P. C., O\u2019Malley, A. J. & Kramer, B. S. Breast-cancer tumor size, overdiagnosis, and mammography screening effectiveness. N. Engl. J. Med. 375, 1438\u20131447. https:\/\/doi.org\/10.1056\/NEJMoa1600249 (2016).","journal-title":"N. Engl. J. Med."},{"key":"82266_CR7","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1158\/1078-0432.CCR-16-3001","volume":"24","author":"LA Emens","year":"2018","unstructured":"Emens, L. A. Breast cancer immunotherapy: facts and hopes. Clin. Cancer Res. 24, 511\u2013520. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-3001 (2018).","journal-title":"Clin. Cancer Res."},{"key":"82266_CR8","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1055\/s-0043-57247","volume":"10","author":"H Singh","year":"2023","unstructured":"Singh, H. Role of molecular targeted therapeutic drugs in treatment of breast cancer: A review article. Glob. Med. Genet. 10, 79\u201386. https:\/\/doi.org\/10.1055\/s-0043-57247 (2023).","journal-title":"Glob. Med. Genet."},{"key":"82266_CR9","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.cancergen.2024.06.002","volume":"286\u2013287","author":"D Sonkin","year":"2024","unstructured":"Sonkin, D., Thomas, A. & Teicher, B. A. Cancer treatments: Past, present, and future. Cancer Genet. 286\u2013287, 18\u201324. https:\/\/doi.org\/10.1016\/j.cancergen.2024.06.002 (2024).","journal-title":"Cancer Genet."},{"key":"82266_CR10","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1177\/548.6505","volume":"96","author":"F Rastelli","year":"2010","unstructured":"Rastelli, F. et al. Triple-negative breast cancer: Current state of the art. Tumori 96, 875\u2013888 (2010).","journal-title":"Tumori"},{"key":"82266_CR11","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1016\/S0140-6736(16)31891-8","volume":"389","author":"N Harbeck","year":"2017","unstructured":"Harbeck, N. & Gnant, M. Breast cancer. Lancet. 389, 1134\u20131150. https:\/\/doi.org\/10.1016\/S0140-6736(16)31891-8 (2017).","journal-title":"Lancet."},{"key":"82266_CR12","doi-asserted-by":"publisher","first-page":"19142","DOI":"10.1038\/s41598-024-70184-1","volume":"14","author":"H Liu","year":"2024","unstructured":"Liu, H., Dong, A., Rasteh, A. M., Wang, P. & Weng, J. Identification of the novel exhausted T cell CD8 + markers in breast cancer. Sci. Rep. 14, 19142. https:\/\/doi.org\/10.1038\/s41598-024-70184-1 (2024).","journal-title":"Sci. Rep."},{"key":"82266_CR13","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.cancergen.2023.07.007","volume":"276\u2013277","author":"X Zeng","year":"2023","unstructured":"Zeng, X. et al. Molecular subtyping and immune score system by a novel pyroptosis-based gene signature precisely predict immune infiltrating, survival and response to immune-checkpoint blockade in breast cancer. Cancer Genet. 276\u2013277, 60\u201369. https:\/\/doi.org\/10.1016\/j.cancergen.2023.07.007 (2023).","journal-title":"Cancer Genet."},{"key":"82266_CR14","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s12943-020-01174-w","volume":"19","author":"J Xu","year":"2020","unstructured":"Xu, J. et al. MIR22HG acts as a tumor suppressor via TGFbeta\/SMAD signaling and facilitates immunotherapy in colorectal cancer. Mol. Cancer. 19, 51. https:\/\/doi.org\/10.1186\/s12943-020-01174-w (2020).","journal-title":"Mol. Cancer."},{"key":"82266_CR15","doi-asserted-by":"publisher","first-page":"188441","DOI":"10.1016\/j.bbcan.2020.188441","volume":"1874","author":"L Zhang","year":"2020","unstructured":"Zhang, L., Ding, J., Li, H. Y., Wang, Z. H. & Wu, J. Immunotherapy for advanced hepatocellular carcinoma, where are we?. Biochim. Biophys. Acta. Rev. Cancer. 1874, 188441. https:\/\/doi.org\/10.1016\/j.bbcan.2020.188441 (2020).","journal-title":"Biochim. Biophys. Acta. Rev. Cancer."},{"key":"82266_CR16","doi-asserted-by":"publisher","first-page":"107886","DOI":"10.1016\/j.intimp.2021.107886","volume":"98","author":"K Barzaman","year":"2021","unstructured":"Barzaman, K. et al. Breast cancer immunotherapy: Current and novel approaches. Int. Immunopharmacol. 98, 107886. https:\/\/doi.org\/10.1016\/j.intimp.2021.107886 (2021).","journal-title":"Int. Immunopharmacol."},{"key":"82266_CR17","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1158\/0008-5472.CAN-16-2379","volume":"77","author":"X Zhao","year":"2017","unstructured":"Zhao, X. & Subramanian, S. Intrinsic resistance of solid tumors to immune checkpoint blockade therapy. Cancer Res. 77, 817\u2013822. https:\/\/doi.org\/10.1158\/0008-5472.CAN-16-2379 (2017).","journal-title":"Cancer Res."},{"key":"82266_CR18","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/s1074-7613(00)80089-8","volume":"11","author":"H Nishimura","year":"1999","unstructured":"Nishimura, H., Nose, M., Hiai, H., Minato, N. & Honjo, T. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity. 11, 141\u2013151. https:\/\/doi.org\/10.1016\/s1074-7613(00)80089-8 (1999).","journal-title":"Immunity."},{"key":"82266_CR19","doi-asserted-by":"publisher","first-page":"728","DOI":"10.3978\/j.issn.2218-6751.2015.12.04","volume":"4","author":"M Santarpia","year":"2015","unstructured":"Santarpia, M. et al. Programmed cell death protein-1\/programmed cell death ligand-1 pathway inhibition and predictive biomarkers: understanding transforming growth factor-beta role. Transl. Lung Cancer Res. 4, 728\u2013742. https:\/\/doi.org\/10.3978\/j.issn.2218-6751.2015.12.04 (2015).","journal-title":"Transl. Lung Cancer Res."},{"key":"82266_CR20","doi-asserted-by":"publisher","DOI":"10.1042\/BSR20201054","author":"J Fang","year":"2020","unstructured":"Fang, J. et al. Prognostic value of immune checkpoint molecules in breast cancer. Biosci. Rep. https:\/\/doi.org\/10.1042\/BSR20201054 (2020)."},{"key":"82266_CR21","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1007\/s00262-020-02736-z","volume":"70","author":"D Kwapisz","year":"2021","unstructured":"Kwapisz, D. Pembrolizumab and atezolizumab in triple-negative breast cancer. Cancer Immunol. Immunother. 70, 607\u2013617. https:\/\/doi.org\/10.1007\/s00262-020-02736-z (2021).","journal-title":"Cancer Immunol. Immunother."},{"key":"82266_CR22","doi-asserted-by":"publisher","first-page":"116543","DOI":"10.1016\/j.lfs.2019.116543","volume":"231","author":"H Triki","year":"2019","unstructured":"Triki, H. et al. CD155 expression in human breast cancer: Clinical significance and relevance to natural killer cell infiltration. Life Sci. 231, 116543. https:\/\/doi.org\/10.1016\/j.lfs.2019.116543 (2019).","journal-title":"Life Sci."},{"key":"82266_CR23","doi-asserted-by":"publisher","first-page":"e2313693120","DOI":"10.1073\/pnas.2313693120","volume":"120","author":"S Wang","year":"2023","unstructured":"Wang, S. et al. ENPP1 is an innate immune checkpoint of the anticancer cGAMP-STING pathway in breast cancer. Proc. Natl. Acad. Sci. U S A. 120, e2313693120. https:\/\/doi.org\/10.1073\/pnas.2313693120 (2023).","journal-title":"Proc. Natl. Acad. Sci. U S A."},{"key":"82266_CR24","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1016\/j.celrep.2018.03.096","volume":"23","author":"K Liu","year":"2018","unstructured":"Liu, K. et al. Mutual stabilization between TRIM9 short isoform and MKK6 Potentiates p38 signaling to synergistically suppress glioblastoma progression. Cell Rep. 23, 838\u2013851. https:\/\/doi.org\/10.1016\/j.celrep.2018.03.096 (2018).","journal-title":"Cell Rep."},{"key":"82266_CR25","doi-asserted-by":"publisher","first-page":"2264","DOI":"10.1158\/0008-5472.CAN-05-3676","volume":"66","author":"JA Hickson","year":"2006","unstructured":"Hickson, J. A. et al. The p38 kinases MKK4 and MKK6 suppress metastatic colonization in human ovarian carcinoma. Cancer Res. 66, 2264\u20132270. https:\/\/doi.org\/10.1158\/0008-5472.CAN-05-3676 (2006).","journal-title":"Cancer Res."},{"key":"82266_CR26","doi-asserted-by":"publisher","first-page":"10800","DOI":"10.1093\/nar\/gkab835","volume":"49","author":"D Szklarczyk","year":"2021","unstructured":"Szklarczyk, D. et al. Correction to \u2018The STRING database in 2021: customizable protein-protein networks, and functional characterization of user-uploaded gene\/measurement sets\u2019. Nucleic Acids Res. 49, 10800. https:\/\/doi.org\/10.1093\/nar\/gkab835 (2021).","journal-title":"Nucleic Acids Res."},{"key":"82266_CR27","unstructured":"Ben-Hur, A., Elisseeff, A. & Guyon, I. A stability based method for discovering structure in clustered data. Pac. Symp. Biocomput. 6\u201317. ISSN:2335-6928, PMID:11928511 (2002)."},{"key":"82266_CR28","doi-asserted-by":"publisher","first-page":"771301","DOI":"10.3389\/fgene.2021.771301","volume":"12","author":"G Malenova","year":"2021","unstructured":"Malenova, G., Rowson, D. & Boeva, V. Exploring pathway-based group lasso for cancer survival analysis: A special case of multi-task learning. Front Genet. 12, 771301. https:\/\/doi.org\/10.3389\/fgene.2021.771301 (2021).","journal-title":"Front Genet."},{"key":"82266_CR29","doi-asserted-by":"publisher","first-page":"19055","DOI":"10.1038\/s41598-023-45774-0","volume":"13","author":"H Liu","year":"2023","unstructured":"Liu, H. & Tang, T. MAPK signaling pathway-based glioma subtypes, machine-learning risk model, and key hub proteins identification. Sci. Rep. 13, 19055. https:\/\/doi.org\/10.1038\/s41598-023-45774-0 (2023).","journal-title":"Sci. Rep."},{"key":"82266_CR30","first-page":"2140","volume":"15","author":"H Liu","year":"2023","unstructured":"Liu, H. & Tang, T. A bioinformatic study of IGFBPs in glioma regarding their diagnostic, prognostic, and therapeutic prediction value. Am. J. Transl. Res. 15, 2140\u20132155 (2023).","journal-title":"Am. J. Transl. Res."},{"key":"82266_CR31","doi-asserted-by":"publisher","first-page":"1438198","DOI":"10.3389\/fimmu.2024.1438198","volume":"15","author":"W Shao","year":"2024","unstructured":"Shao, W. et al. Single-cell RNA sequencing reveals that MYBL2 in malignant epithelial cells is involved in the development and progression of ovarian cancer. Front. Immunol. 15, 1438198. https:\/\/doi.org\/10.3389\/fimmu.2024.1438198 (2024).","journal-title":"Front. Immunol."},{"key":"82266_CR32","doi-asserted-by":"publisher","first-page":"1351287","DOI":"10.3389\/fimmu.2024.1351287","volume":"15","author":"Z Lin","year":"2024","unstructured":"Lin, Z. et al. Decoding the tumor microenvironment and molecular mechanism: unraveling cervical cancer subpopulations and prognostic signatures through scRNA-Seq and bulk RNA-seq analyses. Front. Immunol. 15, 1351287. https:\/\/doi.org\/10.3389\/fimmu.2024.1351287 (2024).","journal-title":"Front. Immunol."},{"key":"82266_CR33","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.cancergen.2023.10.001","volume":"278\u2013279","author":"H Liu","year":"2023","unstructured":"Liu, H. & Tang, T. Pan-cancer genetic analysis of disulfidptosis-related gene set. Cancer Genet. 278\u2013279, 91\u2013103. https:\/\/doi.org\/10.1016\/j.cancergen.2023.10.001 (2023).","journal-title":"Cancer Genet."},{"key":"82266_CR34","doi-asserted-by":"publisher","first-page":"1434450","DOI":"10.3389\/fimmu.2024.1434450","volume":"15","author":"F Zhao","year":"2024","unstructured":"Zhao, F. et al. Elucidating the role of tumor-associated ALOX5+ mast cells with transformative function in cervical cancer progression via single-cell RNA sequencing. Front. Immunol. 15, 1434450. https:\/\/doi.org\/10.3389\/fimmu.2024.1434450 (2024).","journal-title":"Front. Immunol."},{"key":"82266_CR35","doi-asserted-by":"publisher","first-page":"1458638","DOI":"10.3389\/fimmu.2024.1458638","volume":"15","author":"X Li","year":"2024","unstructured":"Li, X. et al. Unveiling the cellular landscape: insights from single-cell RNA sequencing in multiple myeloma. Front. Immunol. 15, 1458638. https:\/\/doi.org\/10.3389\/fimmu.2024.1458638 (2024).","journal-title":"Front. Immunol."},{"key":"82266_CR36","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s12672-024-01286-5","volume":"15","author":"L Sun","year":"2024","unstructured":"Sun, L. et al. Single-cell RNA sequencing explored potential therapeutic targets by revealing the tumor microenvironment of neuroblastoma and its expression in cell death. Discov. Oncol. 15, 409. https:\/\/doi.org\/10.1007\/s12672-024-01286-5 (2024).","journal-title":"Discov. Oncol."},{"key":"82266_CR37","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1186\/s13059-014-0431-1","volume":"15","author":"HR Ali","year":"2014","unstructured":"Ali, H. R. et al. Genome-driven integrated classification of breast cancer validated in over 7,500 samples. Genome Biol. 15, 431. https:\/\/doi.org\/10.1186\/s13059-014-0431-1 (2014).","journal-title":"Genome Biol."},{"key":"82266_CR38","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/s10549-010-0746-x","volume":"120","author":"EA Rakha","year":"2010","unstructured":"Rakha, E. A., Reis-Filho, J. S. & Ellis, I. O. Combinatorial biomarker expression in breast cancer. Breast Cancer Res. Treat. 120, 293\u2013308. https:\/\/doi.org\/10.1007\/s10549-010-0746-x (2010).","journal-title":"Breast Cancer Res. Treat."},{"key":"82266_CR39","doi-asserted-by":"publisher","first-page":"2206","DOI":"10.1093\/annonc\/mdt303","volume":"24","author":"A Goldhirsch","year":"2013","unstructured":"Goldhirsch, A. et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann. Oncol. 24, 2206\u20132223. https:\/\/doi.org\/10.1093\/annonc\/mdt303 (2013).","journal-title":"Ann. Oncol."},{"key":"82266_CR40","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1111\/j.1365-2559.2007.02897.x","volume":"52","author":"SJ Payne","year":"2008","unstructured":"Payne, S. J., Bowen, R. L., Jones, J. L. & Wells, C. A. Predictive markers in breast cancer\u2013the present. Histopathology. 52, 82\u201390. https:\/\/doi.org\/10.1111\/j.1365-2559.2007.02897.x (2008).","journal-title":"Histopathology."},{"key":"82266_CR41","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.cancergen.2023.03.002","volume":"274\u2013275","author":"H Liu","year":"2023","unstructured":"Liu, H. Expression and potential immune involvement of cuproptosis in kidney renal clear cell carcinoma. Cancer Genet. 274\u2013275, 21\u201325. https:\/\/doi.org\/10.1016\/j.cancergen.2023.03.002 (2023).","journal-title":"Cancer Genet."},{"key":"82266_CR42","doi-asserted-by":"publisher","first-page":"858756","DOI":"10.3389\/fonc.2022.858756","volume":"12","author":"H Liu","year":"2022","unstructured":"Liu, H. & Weng, J. A pan-cancer bioinformatic analysis of rad51 regarding the values for diagnosis, prognosis, and therapeutic prediction. Front. Oncol. 12, 858756. https:\/\/doi.org\/10.3389\/fonc.2022.858756 (2022).","journal-title":"Front. Oncol."},{"key":"82266_CR43","doi-asserted-by":"publisher","first-page":"280","DOI":"10.3389\/fcell.2020.00280","volume":"8","author":"Z Zhang","year":"2020","unstructured":"Zhang, Z. et al. Over-expression and prognostic significance of HHLA2, a new immune checkpoint molecule, in human clear cell renal cell carcinoma. Front. Cell Dev. Biol. 8, 280. https:\/\/doi.org\/10.3389\/fcell.2020.00280 (2020).","journal-title":"Front. Cell Dev. Biol."},{"key":"82266_CR44","doi-asserted-by":"publisher","first-page":"688215","DOI":"10.3389\/fimmu.2021.688215","volume":"12","author":"X Zhou","year":"2021","unstructured":"Zhou, X. et al. A Pan-Cancer Analysis of CD161, a Potential New Immune Checkpoint. Front Immunol. 12, 688215. https:\/\/doi.org\/10.3389\/fimmu.2021.688215 (2021).","journal-title":"Front Immunol."},{"key":"82266_CR45","doi-asserted-by":"publisher","first-page":"6375","DOI":"10.1158\/0008-5472.CAN-17-0381","volume":"77","author":"W He","year":"2017","unstructured":"He, W. et al. CD155T\/TIGIT signaling regulates CD8(+) T-cell metabolism and promotes tumor progression in human gastric cancer. Cancer Res. 77, 6375\u20136388. https:\/\/doi.org\/10.1158\/0008-5472.CAN-17-0381 (2017).","journal-title":"Cancer Res."},{"key":"82266_CR46","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/S1470-2045(18)30351-6","volume":"19","author":"AX Zhu","year":"2018","unstructured":"Zhu, A. X. et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): A non-randomised, open-label phase 2 trial. Lancet Oncol. 19, 940\u2013952. https:\/\/doi.org\/10.1016\/S1470-2045(18)30351-6 (2018).","journal-title":"Lancet Oncol."},{"key":"82266_CR47","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1002\/cam4.3718","volume":"10","author":"Y Geng","year":"2021","unstructured":"Geng, Y. et al. Safety and Efficacy of PD-1\/PD-L1 inhibitors combined with radiotherapy in patients with non-small-cell lung cancer: a systematic review and meta-analysis. Cancer Med. 10, 1222\u20131239. https:\/\/doi.org\/10.1002\/cam4.3718 (2021).","journal-title":"Cancer Med."},{"key":"82266_CR48","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1038\/nri3470","volume":"13","author":"TL Murphy","year":"2013","unstructured":"Murphy, T. L., Tussiwand, R. & Murphy, K. M. Specificity through cooperation: BATF-IRF interactions control immune-regulatory networks. Nat. Rev. Immunol. 13, 499\u2013509. https:\/\/doi.org\/10.1038\/nri3470 (2013).","journal-title":"Nat. Rev. Immunol."},{"key":"82266_CR49","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1038\/s41590-021-00964-8","volume":"22","author":"H Seo","year":"2021","unstructured":"Seo, H. et al. BATF and IRF4 cooperate to counter exhaustion in tumor-infiltrating CAR T cells. Nat. Immunol. 22, 983\u2013995. https:\/\/doi.org\/10.1038\/s41590-021-00964-8 (2021).","journal-title":"Nat. Immunol."},{"key":"82266_CR50","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1038\/s41375-018-0045-9","volume":"32","author":"N Schleussner","year":"2018","unstructured":"Schleussner, N. et al. The AP-1-BATF and -BATF3 module is essential for growth, survival and TH17\/ILC3 skewing of anaplastic large cell lymphoma. Leukemia. 32, 1994\u20132007. https:\/\/doi.org\/10.1038\/s41375-018-0045-9 (2018).","journal-title":"Leukemia."},{"key":"82266_CR51","doi-asserted-by":"publisher","first-page":"260","DOI":"10.4110\/in.2015.15.5.260","volume":"15","author":"M Gil","year":"2015","unstructured":"Gil, M. et al. Engagement of CD99 reduces AP-1 activity by inducing BATF in the human multiple myeloma cell line RPMI8226. Immune Netw. 15, 260\u2013267. https:\/\/doi.org\/10.4110\/in.2015.15.5.260 (2015).","journal-title":"Immune Netw."},{"key":"82266_CR52","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1084\/jem.173.1.7","volume":"173","author":"A de la Hera","year":"1991","unstructured":"de la Hera, A., Muller, U., Olsson, C., Isaaz, S. & Tunnacliffe, A. Structure of the T cell antigen receptor (TCR): two CD3 epsilon subunits in a functional TCR\/CD3 complex. J. Exp. Med. 173, 7\u201317. https:\/\/doi.org\/10.1084\/jem.173.1.7 (1991).","journal-title":"J. Exp. Med."},{"key":"82266_CR53","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1002\/ijc.30046","volume":"139","author":"D Upreti","year":"2016","unstructured":"Upreti, D., Zhang, M. L., Bykova, E., Kung, S. K. & Pathak, K. A. Change in CD3zeta-chain expression is an independent predictor of disease status in head and neck cancer patients. Int. J. Cancer. 139, 122\u2013129. https:\/\/doi.org\/10.1002\/ijc.30046 (2016).","journal-title":"Int. J. Cancer."},{"key":"82266_CR54","doi-asserted-by":"publisher","DOI":"10.1042\/BSR20202898","author":"Z Zhu","year":"2021","unstructured":"Zhu, Z. et al. Comprehensive analysis reveals a prognostic and therapeutic biomarker CD3D in the breast carcinoma microenvironment. Biosci. Rep. https:\/\/doi.org\/10.1042\/BSR20202898 (2021)."},{"key":"82266_CR55","doi-asserted-by":"publisher","first-page":"25","DOI":"10.2217\/imt-2019-0145","volume":"12","author":"Y Yang","year":"2020","unstructured":"Yang, Y. et al. CD3D is associated with immune checkpoints and predicts favorable clinical outcome in colon cancer. Immunotherapy. 12, 25\u201335. https:\/\/doi.org\/10.2217\/imt-2019-0145 (2020).","journal-title":"Immunotherapy."},{"key":"82266_CR56","doi-asserted-by":"publisher","first-page":"4393","DOI":"10.4049\/jimmunol.147.12.4393","volume":"147","author":"LP Yu","year":"1991","unstructured":"Yu, L. P. & Sheehy, M. J. The cryptic HLA-DQA2 (\u201cDX alpha\u201d) gene is expressed in human B cell lines. J. Immunol. 147, 4393\u20134397 (1991).","journal-title":"J. Immunol."},{"key":"82266_CR57","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/s1046-2023(02)00345-6","volume":"29","author":"RF Wang","year":"2003","unstructured":"Wang, R. F. Identification of MHC class II-restricted tumor antigens recognized by CD4+ T cells. Methods. 29, 227\u2013235. https:\/\/doi.org\/10.1016\/s1046-2023(02)00345-6 (2003).","journal-title":"Methods."},{"key":"82266_CR58","doi-asserted-by":"publisher","first-page":"3903","DOI":"10.4049\/jimmunol.1103048","volume":"188","author":"C Lenormand","year":"2012","unstructured":"Lenormand, C. et al. HLA-DQA2 and HLA-DQB2 genes are specifically expressed in human Langerhans cells and encode a new HLA class II molecule. J. Immunol. 188, 3903\u20133911. https:\/\/doi.org\/10.4049\/jimmunol.1103048 (2012).","journal-title":"J. Immunol."},{"key":"82266_CR59","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1016\/j.cellsig.2009.12.008","volume":"22","author":"E Shaulian","year":"2010","unstructured":"Shaulian, E. AP-1\u2013The Jun proteins: Oncogenes or tumor suppressors in disguise?. Cell Signal. 22, 894\u2013899. https:\/\/doi.org\/10.1016\/j.cellsig.2009.12.008 (2010).","journal-title":"Cell Signal."},{"key":"82266_CR60","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/nrc2681","volume":"10","author":"P Lopez-Bergami","year":"2010","unstructured":"Lopez-Bergami, P., Lau, E. & Ronai, Z. Emerging roles of ATF2 and the dynamic AP1 network in cancer. Nat. Rev. Cancer. 10, 65\u201376. https:\/\/doi.org\/10.1038\/nrc2681 (2010).","journal-title":"Nat. Rev. Cancer."},{"key":"82266_CR61","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1158\/1541-7786.MCR-15-0423","volume":"14","author":"L Malorni","year":"2016","unstructured":"Malorni, L. et al. Blockade of AP-1 potentiates endocrine therapy and overcomes resistance. Mol. Cancer Res. 14, 470\u2013481. https:\/\/doi.org\/10.1158\/1541-7786.MCR-15-0423 (2016).","journal-title":"Mol. Cancer Res."},{"key":"82266_CR62","doi-asserted-by":"publisher","first-page":"4209","DOI":"10.2174\/1381612823666170720113216","volume":"23","author":"C Quan","year":"2017","unstructured":"Quan, C. et al. Protein kinases as tumor biomarkers and therapeutic targets. Curr. Pharm. Des. 23, 4209\u20134225. https:\/\/doi.org\/10.2174\/1381612823666170720113216 (2017).","journal-title":"Curr. Pharm. Des."},{"key":"82266_CR63","doi-asserted-by":"publisher","first-page":"80","DOI":"10.3389\/fcell.2017.00080","volume":"5","author":"A Cuenda","year":"2017","unstructured":"Cuenda, A., Lizcano, J. M. & Lozano, J. Editorial: mitogen activated protein kinases. Front. Cell Dev. Biol. 5, 80. https:\/\/doi.org\/10.3389\/fcell.2017.00080 (2017).","journal-title":"Front. Cell Dev. Biol."},{"key":"82266_CR64","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1152\/physrev.00028.2011","volume":"92","author":"JM Kyriakis","year":"2012","unstructured":"Kyriakis, J. M. & Avruch, J. Mammalian MAPK signal transduction pathways activated by stress and inflammation: a 10-year update. Physiol Rev. 92, 689\u2013737. https:\/\/doi.org\/10.1152\/physrev.00028.2011 (2012).","journal-title":"Physiol Rev."},{"key":"82266_CR65","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.cellsig.2018.08.008","volume":"51","author":"S Lin","year":"2018","unstructured":"Lin, S. et al. Pharmacological targeting of p38 MAP-Kinase 6 (MAP2K6) inhibits the growth of esophageal adenocarcinoma. Cell Signal. 51, 222\u2013232. https:\/\/doi.org\/10.1016\/j.cellsig.2018.08.008 (2018).","journal-title":"Cell Signal."},{"key":"82266_CR66","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1097\/IGC.0000000000001003","volume":"27","author":"Y Guo","year":"2017","unstructured":"Guo, Y. et al. MAP2K6-FP Enhances the sensitiveness of paclitaxel for ovarian cancer via inducing autophagy. Int. J. Gynecol. Cancer. 27, 1082\u20131087. https:\/\/doi.org\/10.1097\/IGC.0000000000001003 (2017).","journal-title":"Int. J. Gynecol. Cancer."},{"key":"82266_CR67","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.2174\/1871520615666150629100405","volume":"15","author":"J Yuan","year":"2015","unstructured":"Yuan, J. et al. Mitogen-activated protein kinase kinase 6-fusion protein (MAP2K6-FP) potentiates the anti-tumor effects of paclitaxel in ovarian cancer. Anticancer Agents Med Chem. 15, 1308\u20131316. https:\/\/doi.org\/10.2174\/1871520615666150629100405 (2015).","journal-title":"Anticancer Agents Med Chem."},{"key":"82266_CR68","doi-asserted-by":"publisher","first-page":"416","DOI":"10.3109\/07357907.2014.933236","volume":"32","author":"AA Parray","year":"2014","unstructured":"Parray, A. A. et al. MKK6 is upregulated in human esophageal, stomach, and colon cancers. Cancer Invest. 32, 416\u2013422. https:\/\/doi.org\/10.3109\/07357907.2014.933236 (2014).","journal-title":"Cancer Invest."},{"key":"82266_CR69","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1084\/jem.20142009","volume":"212","author":"L Mansouri","year":"2015","unstructured":"Mansouri, L. et al. Functional loss of IkappaBepsilon leads to NF-kappaB deregulation in aggressive chronic lymphocytic leukemia. J. Exp. Med. 212, 833\u2013843. https:\/\/doi.org\/10.1084\/jem.20142009 (2015).","journal-title":"J. Exp. Med."},{"key":"82266_CR70","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.semcancer.2016.07.005","volume":"39","author":"L Mansouri","year":"2016","unstructured":"Mansouri, L., Papakonstantinou, N., Ntoufa, S., Stamatopoulos, K. & Rosenquist, R. NF-kappaB activation in chronic lymphocytic leukemia: A point of convergence of external triggers and intrinsic lesions. Semin. Cancer Biol. 39, 40\u201348. https:\/\/doi.org\/10.1016\/j.semcancer.2016.07.005 (2016).","journal-title":"Semin. Cancer Biol."},{"key":"82266_CR71","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1158\/2159-8290.CD-14-0104","volume":"4","author":"F Damm","year":"2014","unstructured":"Damm, F. et al. Acquired initiating mutations in early hematopoietic cells of CLL patients. Cancer Discov.. 4, 1088\u20131101. https:\/\/doi.org\/10.1158\/2159-8290.CD-14-0104 (2014).","journal-title":"Cancer Discov.."},{"key":"82266_CR72","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-2123","author":"RD Morin","year":"2016","unstructured":"Morin, R. D. et al. Genetic Landscapes of Relapsed and Refractory Diffuse Large B-Cell Lymphomas. Clin. Cancer Res. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-2123 (2016).","journal-title":"Clin. Cancer Res."},{"key":"82266_CR73","doi-asserted-by":"publisher","first-page":"2666","DOI":"10.1182\/blood-2016-03-704528","volume":"128","author":"L Mansouri","year":"2016","unstructured":"Mansouri, L. et al. Frequent NFKBIE deletions are associated with poor outcome in primary mediastinal B-cell lymphoma. Blood. 128, 2666\u20132670. https:\/\/doi.org\/10.1182\/blood-2016-03-704528 (2016).","journal-title":"Blood."},{"key":"82266_CR74","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1038\/s41375-024-02224-8","volume":"38","author":"A Bonato","year":"2024","unstructured":"Bonato, A. et al. NFKBIE mutations are selected by the tumor microenvironment and contribute to immune escape in chronic lymphocytic leukemia. Leukemia. 38, 1511\u20131521. https:\/\/doi.org\/10.1038\/s41375-024-02224-8 (2024).","journal-title":"Leukemia."},{"key":"82266_CR75","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1517\/14728222.2010.492779","volume":"14","author":"JV Kichina","year":"2010","unstructured":"Kichina, J. V., Goc, A., Al-Husein, B., Somanath, P. R. & Kandel, E. S. PAK1 as a therapeutic target. Expert Opin. Ther. Targets. 14, 703\u2013725. https:\/\/doi.org\/10.1517\/14728222.2010.492779 (2010).","journal-title":"Expert Opin. Ther. Targets."},{"key":"82266_CR76","doi-asserted-by":"publisher","DOI":"10.1210\/endocr\/bqaa105","author":"L Bautista","year":"2020","unstructured":"Bautista, L., Knippler, C. M. & Ringel, M. D. p21-activated kinases in thyroid cancer. Endocrinology. https:\/\/doi.org\/10.1210\/endocr\/bqaa105 (2020).","journal-title":"Endocrinology."},{"key":"82266_CR77","doi-asserted-by":"publisher","DOI":"10.4161\/sgtp.28003","author":"CK Rane","year":"2014","unstructured":"Rane, C. K. & Minden, A. P21 activated kinases: structure, regulation, and functions. Small GTPases. https:\/\/doi.org\/10.4161\/sgtp.28003 (2014).","journal-title":"Small GTPases."},{"key":"82266_CR78","doi-asserted-by":"publisher","first-page":"3025","DOI":"10.1074\/jbc.M112.424770","volume":"288","author":"A Goc","year":"2013","unstructured":"Goc, A. et al. P21 activated kinase-1 (Pak1) promotes prostate tumor growth and microinvasion via inhibition of transforming growth factor beta expression and enhanced matrix metalloproteinase 9 secretion. J. Biol. Chem. 288, 3025\u20133035. https:\/\/doi.org\/10.1074\/jbc.M112.424770 (2013).","journal-title":"J. Biol. Chem."},{"key":"82266_CR79","doi-asserted-by":"publisher","first-page":"4049","DOI":"10.1016\/j.semcancer.2018.01.006","volume":"54","author":"CK Rane","year":"2019","unstructured":"Rane, C. K. & Minden, A. P21 activated kinase signaling in cancer. Semin Cancer Biol. 54, 4049. https:\/\/doi.org\/10.1016\/j.semcancer.2018.01.006 (2019).","journal-title":"Semin Cancer Biol."},{"key":"82266_CR80","doi-asserted-by":"publisher","first-page":"167236","DOI":"10.1016\/j.bbadis.2024.167236","volume":"1870","author":"K Wang","year":"2024","unstructured":"Wang, K. et al. PAK1 inhibition increases TRIM21-induced PD-L1 degradation and enhances responses to anti-PD-1 therapy in pancreatic cancer. Biochim. Biophys. Acta Mol. Basis Dis. 1870, 167236. https:\/\/doi.org\/10.1016\/j.bbadis.2024.167236 (2024).","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"key":"82266_CR81","doi-asserted-by":"publisher","first-page":"768","DOI":"10.20517\/cdr.2023.58","volume":"6","author":"RS Wong","year":"2023","unstructured":"Wong, R. S., Ong, R. J. & Lim, J. S. Immune checkpoint inhibitors in breast cancer: development, mechanisms of resistance and potential management strategies. Cancer Drug Resist. 6, 768\u2013787. https:\/\/doi.org\/10.20517\/cdr.2023.58 (2023).","journal-title":"Cancer Drug Resist."},{"key":"82266_CR82","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s40364-024-00620-x","volume":"12","author":"H Liu","year":"2024","unstructured":"Liu, H., Weng, J., Huang, C. L. & Jackson, A. P. Voltage-gated sodium channels in cancers. Biomark Res. 12, 70. https:\/\/doi.org\/10.1186\/s40364-024-00620-x (2024).","journal-title":"Biomark Res."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-82266-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-82266-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-82266-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,28]],"date-time":"2024-12-28T13:04:22Z","timestamp":1735391062000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-82266-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,28]]},"references-count":82,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["82266"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-82266-1","relation":{"references":[{"id-type":"uri","id":"","asserted-by":"subject"},{"id-type":"uri","id":"","asserted-by":"subject"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,28]]},"assertion":[{"value":"13 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"31065"}}